Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment

NCT01211587 is registered in ClinicalTrials.gov with Newron Pharmaceuticals SPA as lead sponsor.

NCT NCT01211587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01211587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment
Lead sponsor
Newron Pharmaceuticals SPA
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
Not reported
Enrollment
103 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease with cognitive impairments